Wave Life Sciences, Inc. (WVE)
NASDAQ: WVE · Real-Time Price · USD
3.460
-0.010 (-0.29%)
At close: Oct 9, 2026, 4:00 PM EDT
3.484
+0.024 (0.69%)
After-hours: Oct 9, 2026, 7:30 PM EDT
Wave Life Sciences Revenue
Wave Life Sciences had revenue of $2.27M in the quarter ending June 30, 2026, a decrease of -73.88%. This brings the company's revenue in the last twelve months to $65.37M, down -30.42% year-over-year. In the year 2025, Wave Life Sciences had annual revenue of $42.73M, down -60.55%. That makes Wave Life Sciences the 25,921st largest company in the world by revenue and 3,582nd in the United States.
Revenue (ttm)
$65.37M
Revenue Growth
-30.42%
P/S Ratio
10.43
Revenue / Employee
$206,218
Employees
317
Market Cap
681.79M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 42.73M | -65.58M | -60.55% |
| Dec 31, 2024 | 108.30M | -5.00M | -4.42% |
| Dec 31, 2023 | 113.31M | 109.66M | 3,005.10% |
| Dec 31, 2022 | 3.65M | -37.32M | -91.09% |
| Dec 31, 2021 | 40.96M | 20.89M | 104.03% |
| Dec 31, 2020 | 20.08M | 4.09M | 25.61% |
| Dec 31, 2019 | 15.98M | 1.57M | 10.89% |
| Dec 31, 2018 | 14.41M | 10.52M | 270.25% |
| Dec 31, 2017 | 3.89M | 2.80M | 256.50% |
| Dec 31, 2016 | 1.09M | 940.00K | 618.42% |
| Dec 31, 2015 | 152.00K | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Pharming Group | 366.48M |
| MiMedx Group | 355.17M |
| Zevra Therapeutics | 136.07M |
| OmniAb | 38.46M |
| Crescent Biopharma | 11.88M |
| Prime Medicine | 4.07M |
WVE News
- 10 days ago - Wave Life Sciences announces FDA feedback supports pathway for WVE-006 - TheFly
- 10 days ago - Wave Life Sciences Announces FDA Feedback Supports Registrational Pathway for WVE-006 (RNA Editing) in AATD - GlobeNewsWire
- 10 days ago - Wave Life Sciences initiated with a Buy at Ladenburg - TheFly
- 11 days ago - Wave Life announces GSK’s selection of siRNA program to transition to GSK - TheFly
- 11 days ago - Wave Life Sciences Announces GSK's Selection of siRNA program to Transition to GSK for Further Development - GlobeNewsWire
- 18 days ago - Wave Life Sciences resumed with a Neutral at JPMorgan - TheFly
- 18 days ago - Wave Life Sciences initiates Phase 2a combination trial of WVE-007 - TheFly
- 18 days ago - Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity - GlobeNewsWire